Preliminary annual report 2018/19
ProInvent teknologiudvikling A/S
CVR-nr. 14 24 89 94
ProInvent A/S has had a very busy 2019 performing 48 customer projects from 30/9 2018 to 30/9 2019. It’s a mix of large-scale epoch-making projects, medium scale projects and minor projects. As many times before leading production companies have chosen ProInvent to be their technological cooperation partner, and we know that our longstanding customer relations shall be seen in the light that year after year we add good benefits to our customers, and we always deliver at competitive prices. Important projects with the purpose of increasing productivity are currently being implemented for Novo Nordisk, Bavarian Nordic, Widex, Ferring Pharmaceuticals, Radiometer Medical, Chr. Hansen, Novozymes, Coloplast, Kopenhagen Fur, Pressalit, Stansomatic, Topsil GlobalWafers, Umicore and Haldor Topsøe.
ProInvent’s activity level is growing 15% per year, and this is reflected in gross profit, number of employees and generates approximately turn over of DKK 42,5 m this financial year. The high level of activities is due to the fact that as in previous years ProInvent’s employees have contributed a special commitment throughout the year and this has resulted in well-solved projects and satisfied customers.
Development in finances (preliminary)
- Turn over amounts to DKK 42,5 m
- Operating profit amounts to DKK 200.000
- Equity amounts to DKK 4,5 m
- Total assets amount to DKK 12 m
- ProInvent’s solvency ratio is 40%
- ProInvent’s liquidity ratio is 120%
In 2019 ProInvent has invested in growth generally by hiring and introducing 15 new employees, all specialists in their field. A major part of the investment was spent to establish the new Product Development Department and to grow the Deep Learning based Vision Department. Operating profit of the year is therefore less than normal, but on this background satisfactory.
Management considers equity, solvency ratio and liquidity ratio highly satisfactory.
ProInvent is geared to projects in the GMP- and GAMP environment, and this has resulted in a higher project portfolio from the pharmaceutical,- and medico/device industries, and this means that we continually make ourselves acquainted with each single customer’s QMS structure and perform the necessary documentation which provides the basis for easy-going performance of qualification and validation.
ProInvent has a really talented team, now counting 50 employees and based on a really good order book/order intake management is planning further controlled growth and expects that the new financial year will achieve a higher activity level too, and definitely better operational earnings.
Annual report 2018/19 will be signed and posted: December 12th 2019
See annual report 2017/18 here
November 7th 2019
Leif Dalum, CEO